<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
----------------
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended June 30, 1999
OR
[ ] TRANSITIONAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _________ to _________.
Commission File Number: 0-27972
TREGA BIOSCIENCES, INC.
----------------------------------------------------
(Exact Name of Registrant as Specified in its charter)
DELAWARE 51-0336233
------------------------------- -------------------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
9880 CAMPUS POINT DRIVE, SAN DIEGO, CA 92121
(619) 410-6500
- --------------------------------------------------------------------------------
(Address, including zip code, and telephone, including area code,
of registrant's principal executive offices)
Indicate by check mark whether the Registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Class Outstanding at June 30, 1999
- ------------------------------ ----------------------------
Common Stock, $0.001 par value 18,072,095
<PAGE>
This Amended Report on Form 10-Q, for the quarter ending June 30, 1999, is being
filed for the purpose of including information for Item 4 of Part II.
PART II. OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
The Annual Meeting of Stockholders of the Company (the "Annual Meeting")
was held on May 18, 1999 in San Diego, California.
Item 1. - Election of Directors
Each of the nominees listed was duly elected to the Board of Directors
of the Company at the Annual Meeting by the tally indicated:
<TABLE>
<CAPTION>
CLASS II NOMINEES VOTES IN FAVOR VOTES AGAINST ABSTAIN/NON-VOTES
- ----------------- -------------- ------------- -----------------
<S> <C> <C> <C>
Lawrence D. Muschek 14,590,955 46,500 0
Anders P. Wiklund 14,597,662 39,793 0
</TABLE>
Item 2. - Ratification of the Company's Independent Auditors
<TABLE>
<CAPTION>
VOTES IN FAVOR VOTES AGAINST ABSTAIN/NON-VOTES
-------------- ------------- -----------------
<S> <C> <C>
13,397,157 1,231,904 8,394
</TABLE>
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Trega Biosciences, Inc.
Date: August 23, 1999 /s/ Michael G. Grey
--------------------
Michael G. Grey
President and Chief Executive Officer
(Principal Executive Officer)
/s/ Gerard A. Wills
---------------------
Gerard A. Wills
Vice President, Finance and
Chief Financial Officer
(Principal Financial and Accounting Officer)
3
